Clinical trials: Acromegaly
Acromegaly
Study of MAR002 in Healthy Men
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
- Trial name
- NCT07195175
- Testing
- MAR002
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Marea Therapeutics
Acromegaly Due to Pituitary Adenoma, Difficult Intubation
Ultrasound in Predicting Difficult Intubation in Acromegaly Patients
This is a prospective observational study.The purpose of this study is to predict difficult intubation with ultrasonographic evaluation combined with preoperative physical examination in patients diagnosed with acromegaly and…
- Conditions
- Acromegaly Due to Pituitary Adenoma, Difficult Intubation, Airway Ultrasonography
- Trial name
- NCT07306325
- Testing
- observational study
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Acromegaly
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months.
- Trial name
- NCT04125836
- Testing
- CAM2029 (octreotide subcutaneous depot)
- Where
- 68 sites in United States, Germany and 9 more
- Volunteers
- 135 people
- Sponsor
- Camurus AB
Acromegaly
Reproducibility and Utility of OGTT in Acromegaly
Prospective study of reproducibility and utility of growth hormone inhibition by oral glucose tolerance test for the diagnosis of acromegaly, in acromegalic and non-acromegalic subjects, with a randomized double-blind crossover…
- Trial name
- ACROTEST (NCT04066569)
- Testing
- Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)
- Where
- France
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acromegaly, GEP-NET
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning…
- Trial name
- OXTEND-01 (NCT05364944)
- Testing
- Debio 4126, Sandostatin LAR, Somatuline ATG
- Where
- 14 sites in Denmark, France and 6 more
- Volunteers
- 19 people
- Sponsor
- Debiopharm International SA
Acromegaly Due to Pituitary Adenoma, Acromegaly
Effects of Pasireotide Lar Therapy on Bone Metabolism
Acromegaly, a chronic condition characterized by growth hormone (GH) and, in turn, insulin-like growth factor-1 (IGF-I) excess, is burdened by a series of systemic and metabolic comorbidities that strongly impair quality of life…
- Trial name
- Pasi-Bone (NCT07179926)
- Testing
- morphometric spine radiography
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acromegaly
Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active Acromegaly
This prospective, single-center, crossover study aims to evaluate the metabolic and hormonal effects of a ketogenic diet compared to a Mediterranean diet in patients with active acromegaly.
- Trial name
- NCT07100587
- Testing
- Ketogenic diet, Mediterranean diet
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- University of Palermo
Acromegaly
A Prospective Study of Outcome After Therapy for Acromegaly
The purpose of this study is to evaluate hormone values and other markers of disease activity in a cohort of patients with acromegaly at the time of diagnosis and then prospectively after surgical or other treatment.
- Trial name
- NCT01809808
- Testing
- Surgery for acromegaly, Medications for acromegaly, Total body magnetic resonance imaging
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Columbia University
Acromegaly
Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study
Acromegaly is a rare chronic disease due to excessive secretion of growth hormone (GH) and insulin-like growth factor-I (IGF-I), caused in over 98% of cases by GH-secreting pituitary adenoma.
- Trial name
- ACROMORFO (NCT05964712)
- Testing
- Medical surgery therapy
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Istituto Auxologico Italiano
Acromegaly
A Phase 1 Study of TE-8214 Solution in Healthy Volunteers
This is a Phase 1, first-in-human, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and PK of TE-8214 in healthy volunteers. The study will assess single ascending doses (SAD) of TE-8214.
- Trial name
- NCT06372652
- Testing
- TE-8214 - SAD
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Immunwork, Inc.
Acromegaly
Treatment Patterns and Treatment Outcomes for Acromegaly
This is a human, prospective and retrospective, single-center study of patients who have undergone treatment for acromegaly in New York City since 1981.
- Trial name
- NCT03043586
- Where
- United States
- Volunteers
- 520 people
- Sponsor
- Columbia University
Acromegaly Due to Pituitary Adenoma, Ketogenic Diet
KETOgenic Diet Therapy in Patients With ACROmegaly
Acromegaly is caused by a tumour located at the base of the brain in the pituitary gland that produces too much growth hormone (GH).
- Conditions
- Acromegaly Due to Pituitary Adenoma, Ketogenic Diet, Mediterranean Diet
- Trial name
- KETOACRO (NCT06949891)
- Testing
- Ketogenic diet, Mediterranean diet
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Erasmus Medical Center
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to…
- Trial name
- NCT03792555
- Testing
- Paltusotine
- Where
- 11 sites in United States, Brazil and 6 more
- Volunteers
- 13 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment…
- Trial name
- NCT03789656
- Testing
- Paltusotine
- Where
- 26 sites in United States, Brazil and 10 more
- Volunteers
- 47 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs
The purpose of this study is to test the effect of long-acting somatostatin analog medications, taken by patients with acromegaly or carcinoid syndrome, on growth hormone in comparison to healthy controls who are not receiving…
- Trial name
- NCT01371045
- Testing
- Oral Glucose Tolerance Test (OGTT)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Acromegaly
Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice.
- Trial name
- NCT05431803
- Where
- 12 sites in China
- Volunteers
- 129 people
- Sponsor
- Ipsen
Acromegaly
PegvisOMant and the Immune SystEm (PROMISE)
This is a prospective observational pilot study for the evaluation of immune cells phenotype in acromegalic patients in comparison with a control population and to investigate the impact of disease control and different medical…
- Trial name
- NCT05069324
- Where
- Italy
- Volunteers
- 62 people
- Sponsor
- University of Roma La Sapienza
Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Participants of this study are adults with GEP-NETs and/or acromegaly who were using the Ipsen lanreotide syringe and have transitioned in the last 6 months to the Pharmathen lanreotide syringe, having received at least two…
- Trial name
- BackSOM (NCT06253897)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ipsen
Acromegaly
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
The purpose of this study was to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.
- Trial name
- NCT04522180
- Testing
- GHR-LRX
- Where
- 22 sites in United States, Estonia and 8 more
- Volunteers
- 34 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP